Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.27
+0.00 (0.00%)
AAPL  266.18
+0.00 (0.00%)
AMD  196.60
+0.00 (0.00%)
BAC  51.07
+0.00 (0.00%)
GOOG  311.69
+0.00 (0.00%)
META  637.46
+0.21 (0.03%)
MSFT  384.47
+0.00 (0.00%)
NVDA  191.55
+0.00 (0.00%)
ORCL  141.31
+0.00 (0.00%)
TSLA  399.83
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.